Wakamoto Pharmaceutical (4512) Fundamentals 2026 — P/E 41.8x, Revenue Analysis | SniperIQ
Wakamoto Pharmaceutical (4512) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥9.5B, trading at ¥274.00 on the JPX. This SniperIQ fundamentals page covers Wakamoto Pharmaceutical's valuation (P/E 41.8x, P/B 0.8x), profitability (net margin 2.3%), revenue (¥9.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Wakamoto Pharmaceutical's market cap?
Wakamoto Pharmaceutical (4512) has a market capitalization of approximately ¥9.5B, trading at ¥274.00 on the JPX. Market cap moves with the live share price.
What is Wakamoto Pharmaceutical's P/E ratio?
Wakamoto Pharmaceutical's trailing twelve-month P/E ratio is 41.8x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Wakamoto Pharmaceutical?
Wakamoto Pharmaceutical runs a net profit margin of 2.3%, a gross margin of 47.7%, and an operating margin of 2.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Wakamoto Pharmaceutical generate?
Wakamoto Pharmaceutical reported revenue of ¥9.9B for fiscal year 2025, with net income of ¥227M and earnings per share (EPS) of 6.55. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Wakamoto Pharmaceutical pay a dividend?
Wakamoto Pharmaceutical offers a trailing dividend yield of about 1.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Wakamoto Pharmaceutical financially healthy?
Wakamoto Pharmaceutical carries a debt-to-equity ratio of 0.03x and a current ratio of 3.48x, with a market beta of 0.45. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Wakamoto Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Wakamoto Pharmaceutical (4512) the key facts are: market cap ¥9.5B, P/E 41.8x, revenue ¥9.9B, 52-week range 240-380. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Wakamoto Pharmaceutical's full fundamentals live
Get Wakamoto Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.